MET and non-small cell lung carcinoma: It is reported that the overexpression of c-Met occurs in about 20–25% of patients with NSCLC and persistently stimulates PIK3CA, MAPK, and STAT pathways to bypass EGFR, thereby inducing the malignant progression of the tumor [53].